Please ensure Javascript is enabled for purposes of website accessibility

sterile manufacturing

The U.S. Food and Drug Administration has approved The Ritedose Corp.’s manufacturing and distribution of Tobramycin Inhalation Solution to treat patients 6 years and older with infections of Pseudomonas aeruginosa, a common bacterial infection among cystic fibrosis patients. (Photo/Ritedose)
Nov 4, 2025

Ritedose expands portfolio with new FDA-approved antibiotic

The Ritedose Corp. has received FDA approval to manufacture a new inhalation antibiotic, strengthening its U.S. production and sterile drug portfolio.